Alvotech og Advanz Pharma undirrita samning um markaðssetningu í Evrópu á fyrirhugaðri líftæknilyfjahliðstæðu við Eylea
18 juin 2024 04h00 HE
|
Alvotech
Advanz Pharma fær rétt til markaðssetningar fyrirhugaðrar líftæknilyfjahliðstæðu við Eylea í Evrópu, en Alvotech þróar nú tvær útgáfur lyfsinsAdvanz Pharma mun nýta þekkingu á markaðssetningu...
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
18 juin 2024 04h00 HE
|
Alvotech
Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in EuropeAdvanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
17 juin 2024 09h50 HE
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CBIH a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation.
Alvotech and STADA add to strategic alliance through denosumab partnership
11 juin 2024 04h00 HE
|
Alvotech
STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...
Alvotech og STADA útvíkka samstarf sitt með nýjum samningi um AVT03, fyrirhugaða hliðstæðu við Prolia og Xgeva
11 juin 2024 04h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) og STADA tilkynntu í dag að fyrirtækin hafi útvíkkað samstarf sitt með samningi um markaðssetningu AVT03, fyrirhugaðrar líftæknilyfjahliðstæðu við Prolia og Xgeva (denosumab)...
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
11 juin 2024 04h00 HE
|
Alvotech
STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...
Alvotech gengur frá samningi við alþjóðlega fjárfesta um endurfjármögnun skulda
07 juin 2024 04h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið hafi gert samning um endurfjármögnun skulda við GoldenTree Asset Management, bandarískt eignastýringarfyrirtæki, sem fer fyrir hópi alþjóðlegra...
Alvotech Announces Strategic Refinancing Agreement
07 juin 2024 04h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a...
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
05 juin 2024 15h12 HE
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
“Collaboration in clinical trials ensures data integrity and safety, advancing both organizations' missions and improving patient care,” says Dr. Jennifer
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
29 mai 2024 08h05 HE
|
Alvotech
REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...